Baxalta, a biopharmeceutical company that specializes in treating rare conditions, was spun off from the healthcare giant Baxter International (ranked No. 286 on this yearâ€™s Forutne 500) last July. Earning $6.1 billion in revenue its inaugural year, the young company is looking forward to greater growth as it awaits the conclusion of a $32 billion merger with Shire.
